Editorial: potassium-competitive acid blockers-is there a role for more complete acid suppression?

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE

Publication: Oxford : Wiley-Blackwell
Original Publication: [Oxford, OX] : Blackwell Scientific Publications, [c1987-

Gastric Acid*/metabolism ; Potassium*/metabolism; H(+)-K(+)-Exchanging ATPase/metabolism ; Humans

Comment on: Aliment Pharmacol Ther. 2022 Jun;55(12):1524-1533. (PMID: 35505467)
Comment in: Aliment Pharmacol Ther. 2022 Sep;56(6):1072-1073. (PMID: 35995746)

Chen S, Liu D, Laio A, Li F, Liu C, Li X, et al. The efficacy and safety of keverprazan, a novel potassium competitive acid blocker, in treating erosive oesophagitis: a phase III, randomized, double-blind multicentre study. Aliment Pharmacol Ther. 2022;55:1524-1533.
Abdel-Aziz Y, Metz DC, Howden CW. Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther. 2021;53:794-809.
Laine L, DeVault KR, Katz PO, Mitev S, Lowe J, Hunt B, et al. Double-blind randomized trial of the potassium-competitive acid blocker vonoprazan vs the proton pump inhibitor lansoprazole in US and European patients with erosive esophagitis. Gastroenterology. 2022;162:S-214.
Yi S, Lee H, Jang SB. A novel K+ competitive acid blocker, YH4808 sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomized clinical study in healthy volunteers. Aliment Pharmacol Ther. 2017;46:337-346.
Kim E, Kim A, Yi S, Kim YK, Jang SB, Byun HM, et al. Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects. Eur J Clin Phamacol. 2018;75:1261-872.
Lee KJ, Son BK, Kim GH, Jung HK, Jung HY, Chung IK, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker vs esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49:864-872.
Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, et al. Phase III, randomized, double-blind, multicentre study to evaluate the efficacy and saferty of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69:224-30.

EC 3.6.3.10 (H(+)-K(+)-Exchanging ATPase)
RWP5GA015D (Potassium)

Date Created: 20220822 Date Completed: 20220824 Latest Revision: 20220830

20240513

10.1111/apt.17127

35995736